Skip to content

Effect of remimazolam tosylate on cognitive function after major abdominal surgery in older adults

Effect of remimazolam tosylate on cognitive function after major abdominal surgery in older adults - Effect of remimazolam on postoperative cognitive function

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091313
Enrollment
Unknown
Registered
2024-10-25
Start date
2024-10-30
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction

Interventions

Remimazolam group:Remimazolam group (R group), anesthesia induction and maintenance were treated with remimazolam. Additional medications include sufentanil, etomidate, and vecuronium.
Propofol group:Propofol group (P group), anesthesia induction and maintenance were treated with propofol. Additional medications include sufentanil, etomidate, and vecuronium.

Sponsors

The First People's Hospital of Lianyungang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Age= 65 years old and 2 hours.

Exclusion criteria

Exclusion criteria: (1) Have a history of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or well-diagnosed depression before surgery; (2) Inability to communicate normally due to coma, severe dementia, speech disorder, mental disorder or serious illness; (3) Critical illness (preoperative ASA physical condition classification > grade 3), severe liver dysfunction (Child-C grade) or severe renal dysfunction (preoperative dialysis); (4) Have a history of neurosurgery; (5) History of psychotropic drug abuse.

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative cognitive dysfunction;

Secondary

MeasureTime frame
Postoperative delirium incidence rate;

Countries

China

Contacts

Public ContactKeyao Zhang

The First People's Hospital of Lianyungang

695055042@qq.com+86 195 5215 3301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026